Is erdafitinib currently covered by medical insurance?

Erdafitinib (Erdafitinib) is an oral small molecule targeted drug mainly used to treat specific types of tumors. The drug is indicated for the treatment of urothelial cancer (bladder cancer) with FGFR gene mutations, especially in patients whose disease has progressed after chemotherapy or other therapies. Erdafitinib interferes with the growth and spread of tumor cells by selectively inhibiting the fibroblast growth factor receptor (FGFR). This mechanism makes erdafitinib a new treatment option, bringing hope to patients who have failed to respond to traditional treatments.

In China, the launch of erdafitinib provides a new treatment approach for patients with urothelial cancer. The drug was developed by Johnson & Johnson Pharmaceuticals and has been approved by the National Medical Products Administration. Its trade name is BALVERSA. Common specifications currently on the market include 5mg 28 tablets, 3mg 56 tablets and 4mg*28 tablets to meet the medication needs of different patients. However, although erdafitinib has been marketed in China, it has not yet been included in China's basic medical insurance (medical insurance). This puts many patients under financial pressure because of the high out-of-pocket cost of purchasing the drug.

Many patients may have difficulty seeking treatment because they are not yet covered by insurance. In this case, some patients choose to purchase erdafitinib through foreign channels in order to obtain cheaper or timely treatment options. However, there may be hidden risks in quality and safety when purchasing drugs through informal channels, so patients need to be cautious when choosing, and it is best to make decisions under the guidance of a doctor.

In addition, as the mechanism of action of erdafitinib is further studied, its application in other tumor types may be explored in the future. This also provides potential opportunities for further development and clinical trials of the drug. If more clinical data support the efficacy of erdafitinib in other cancer types, it may prompt relevant departments to re-examine its medical insurance coverage, thereby benefiting more patients.

Reference materials：https://www.balversa.com/